Di.S.SAL Section of Dermatology, University of Genoa, Via Pastore 1, Genoa, Italy.
Section of Dermatology, IRCCS San Martino Policlinic Hospital, Genoa, Italy.
Dermatol Ther. 2020 Jan;33(1):e13190. doi: 10.1111/dth.13190. Epub 2020 Jan 2.
Bullous pemphigoid, mucous membrane pemphigoid, and pemphigus vulgaris are different cutaneous autoimmune blistering diseases, with complex pathogenic mechanisms. In all of them, a type-2 response is thought to have a central role. Interleukin 4 and Interleukin 13 are crucial cytokines in type-2 response. Treatment of these conditions is often challenging. Dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to human interleukin-4 receptor IL-4Rα, has the potential to inhibit both IL-4 and IL-13. We propose IL-4Rα as a theoretical drug target for cutaneous autoimmune bullous diseases.
大疱性类天疱疮、黏膜类天疱疮和寻常型天疱疮是三种不同的皮肤自身免疫性水疱病，具有复杂的发病机制。在所有这些疾病中，都认为 2 型反应起着核心作用。白细胞介素 4 和白细胞介素 13 是 2 型反应中的关键细胞因子。这些疾病的治疗往往具有挑战性。度普利尤单抗是一种重组的全人源 IgG4 单克隆抗体，对人白细胞介素-4 受体（IL-4Rα）具有特异性结合能力，具有抑制白细胞介素 4 和白细胞介素 13 的潜力。我们提出 IL-4Rα 作为皮肤自身免疫性大疱性疾病的理论药物靶点。
